Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Virtual yoga (vYOCAS) intervention for psychological distress: A decentralized digital randomized controlled trial with cancer survivors.

Po-Ju Lin, Alisha Chakrabarti, Lindsey Jean Mattick et al. Jun 01, 2025 pp. 12131-12131 10.1200/jco.2025.43.16_suppl.12131

12131 Background: Psychological distress is highly prevalent among cancer survivors, and it interferes with their ability to recover after treatment and r...

The impacts on prognosis of the relationship between decline in renal function associated with pemetrexed and the ratio of pemetrexed administration.

Yuta Yamanaka, Kenta Murotani, Hiroshige Yoshioka et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20623

e20623 Background: The KEYNOTE 189 regimen of pembrolizumab + pemetrexed + cisplatin/carboplatin is currently being used as first-line chemotherapy for me...

Impact of neuroradiologists’ input on peer review meetings for CNS radiotherapy treatment planning.

Abhishek Mahajan, Chloë May, Shaveta Mehta et al. Jun 01, 2025 pp. 2043-2043 10.1200/jco.2025.43.16_suppl.2043

2043 Background: Evidence shows radiologists’ involvement improves planning accuracy, especially in complex anatomical areas. However, their participation...

RIBBON-UM: Treatment individualisation by EBV stratification in nasopharyngeal carcinoma (NPC): A phase 2, multi-arm umbrella platform trial.

Melvin L.K. Chua, Sze Huey Tan, Enya Ong et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps6123

TPS6123 Background: Induction chemotherapy (IC) and chemoradiotherapy (CRT) is the current standard of care (SOC) for locoregionally advanced NPC (LA-NPC)...

Real world and Appalachian comparison of axicabtagene ciloleucel and lisocabtagene maraleucel in relapsed/refractory diffuse large B-cell lymphoma.

Stephen Lee Yu, Mohammed Abdulhaleem, Zainab Fatima et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19003

e19003 Background: Chimeric antigen receptor T-cell therapies targeting CD19, like Axicabatagene ciloleucel (axicel) and Lisocabtagene maraleucel (lisocel...

Validation of metastatic breast cancer (mBC) diagnosis in structured electronic health record (EHR) data vs chart-curated verification using the IntegraConnect Precision-Q (IC PQ) de-identified database.

Anna Rui, Samantha Eiffert, Anupama Vasudevan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23147

e23147 Background: Leveraging EHR data to study cancer provides details from physician notes and scanned reports not available in claims data. The IC PQ D...

Trial in progress: Sacituzumab govitecan for the treatment of patients with diffuse pleural mesothelioma.

Michael Offin, Esther Redin, Prashasti Agrawal et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps8123

TPS8123 Background: Diffuse pleural mesothelioma (DPM) is an aggressive malignancy with poor outcomes and only three FDA-approved treatments (all first-li...

Peripheral and cutaneous T-cell lymphomas in the United States: A 21-year mortality analysis (1999-2020).

Umaima Cheema, Faiza Fatima, Iqra Shahid et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19055

e19055 Background: Peripheral and cutaneous T-cell lymphomas (PTCL and CTCL) comprise of a vast variety of rare and heterogeneous subtypes of non-Hodgkin...

Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs).

Rohit Thummalapalli, Zeynep Tarcan, Courtney Porfido et al. Jun 01, 2025 pp. 4146-4146 10.1200/jco.2025.43.16_suppl.4146

4146 Background: Delta-like ligand 3 (DLL3) is an emerging target in multiple neuroendocrine cancers including small cell lung cancer but remains underexp...

Clinical efficacy and safety of cadonilimab in the treatment of advanced gynecological malignancies: A retrospective, real-world study.

Yisidan Huang, Yuting Zeng, Can Yang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17652

e17652 Background: Cadonilimab, recognized as the most rapidly developed Chinese bispecific antibody in the field of cervical cancer, received marketing a...

Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age.

Kevin Kalinsky, Mattea Reinisch, Yen-Shen Lu et al. Jun 01, 2025 pp. 516-516 10.1200/jco.2025.43.16_suppl.516

516 Background: The NATALEE trial demonstrated significant invasive disease–free survival benefit with RIB + NSAI vs NSAI alone in patients (pts) with sta...

Prognostic features and clinical panthological factors of cutaneous malignant melanoma.

Hui Jin, Meirong Li, Dan Xiao Li et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21589

e21589 Background: Cutaneous malignant melanoma (CMM), a skin-originating subtype of melanoma, is highly invasive with strong metastatic potential. Acral...

Understanding disparities in survival outcomes for early-onset gastric cancer: A comprehensive multifactorial analysis using SEER database.

Sneha Singh, Hardik Jain, Sangam Sangam et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16148

e16148 Background: Despite a declining overall incidence of gastric cancer in the United States, Early-Onset Gastric Cancer (EOGC), diagnosed in individua...

The EGFR-TKIs treatment challenge in NSCLC: Changes in survival after COVID-19 infection.

Wenjie Tang, Xiaolin Li, Jing Liu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20538

e20538 Background: COVID-19 has emerged as a major public health emergency with long-term impacts, especially on cancer patients who are more susceptible...

Prospective assessment of health-related quality of life in early phase clinical trials.

Udit Nindra, Jun Hee Hong, Joanne Tang et al. Jun 01, 2025 pp. 11118-11118 10.1200/jco.2025.43.16_suppl.11118

11118 Background: Early phase clinical trials (EP-CTs) provide patients with access to novel therapeutics once standard of care options are exhausted or n...

Enterprise-level AI screening for oncology trials: Improving patient identification with OncoLLM.

Grace Westerman, Claire T Verhagen, Haley Heaviland et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13706

e13706 Background: Comprehensive clinical trial screening for all oncology patients is challenging due to multiple factors...

Comprehensive analysis of clinicopathological features and outcomes of hormone positive breast cancer from a tertiary care centre in India.

Aastha Goel, Ajay Gogia, Atul Batra et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12581

e12581 Background: The composite data of clinicopathological features and outcomes in hormone receptor-positive (HR+) breast cancer from a low-middle inco...

Exploring survival outcomes in sarcomatoid hepatocellular carcinomas in the era of immunotherapy.

Ahmed Abdelhakeem, Saivaishnavi Kamatham, Osama M MoSalem et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16330

e16330 Background: Sarcomatoid hepatocellular carcinoma (SHC) is a rare and aggressive variant of hepatocellular carcinoma (HCC), accounting for less than...

Evaluation of surrogate endpoints in muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.

Matthew D. Galsky, Yu Wang, Allison Thompson et al. Jun 01, 2025 pp. 4580-4580 10.1200/jco.2025.43.16_suppl.4580

4580 Background: Overall survival (OS) is the gold-standard efficacy measure in oncology; however, it can take several years for OS data to mature, partic...

Comparison of dual vs. triple oral metronomic chemotherapy using methotrexate, celecoxib with or without erlotinib in advanced head and neck squamous cell cancer: Real-world data and experience from a tertiary care center.

Rishi Prem Nair, Sanjay Santhyavu, Atul Gupta et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18038

e18038 Background: The standard of care for unresectable or metastatic advanced head and neck squamous cell carcinoma (HNCSCC) is either immunotherapy or...

Phase 1 trial of exercise as first-line therapy for hormone receptor (HR)–positive advanced breast cancer (TBCRC 054).

Neil M. Iyengar, Jessica A. Lavery, Adele Carlson et al. Jun 01, 2025 pp. 1088-1088 10.1200/jco.2025.43.16_suppl.1088

1088 Background: Observational studies show post-diagnosis exercise is associated with reduced risk of cancer death in patients with HR-positive breast ca...

Treatment-related changes in salivary CD44 and total protein in patients with oral and oropharyngeal cancer.

Garrett Forman, Janice Jing Huang, Sophia Peifer et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18061

e18061 Background: Prior smaller-scale studies have demonstrated elevated salivary CD44 and total protein (TP) in patients with oral cavity and oropharyng...

Ethnic differences in non-metastatic breast cancer outcomes by tumour subtype: Real-world data from the Singapore Joint Breast Cancer Registry.

Ryan Tan, Whee Sze Ong, Shun Zi Liong et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13772

e13772 Background: Ethnic disparities in breast cancer (BC) are increasingly recognized, with emerging differences among d...

Identification of tissue-resident adaptive NK cells and their association with reduced mortality across diverse solid tumors.

John R. Lozada, Atef Mir Ali, Christine Luo et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14555

e14555 Background: Natural killer (NK) cells are innate lymphocytes that engage in direct cytotoxic responses against malignant cells and promote pro-infl...

Impact of anti-VEGF therapy duration on KRAS/NRAS WT mCRC survival after anti-EGFR therapy.

Sheng-chieh Huang, Shih-Ching Chang, Jeng-Kai Jiang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15549

e15549 Background: First-line anti-EGFR therapy is one of the choice that improves outcomes in KRAS/NRAS wild-type(WT), but evidence on subsequent anti-VE...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page